ResearcherJiangsu UniversityNo recent work listed

Min Xu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0576-497X; OpenAlex author ID A5025296435. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2023: 2 papers

Papers 2

A real-world study of anlotinib combined with GS regimen as first-line treatment for advanced pancreatic cancer. Co-author DOI 10.3389/fendo.2023.1110624 ↗
NCAPG2 could be an immunological and prognostic biomarker: From pan-cancer analysis to pancreatic cancer validation. Last author DOI 10.3389/fimmu.2023.1097403 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Qi Wang · 1 shared paper, 2023 · strength 0.18
- Paper NCAPG2 could be an immunological and prognostic biomarker: From pan-cancer analysis to pancreatic cancer validation. DOI 10.3389/fimmu.2023.1097403 ↗
Xu‐Feng Huang · 1 shared paper, 2023 · strength 0.18
- Paper NCAPG2 could be an immunological and prognostic biomarker: From pan-cancer analysis to pancreatic cancer validation. DOI 10.3389/fimmu.2023.1097403 ↗
Shujing Zhou · 1 shared paper, 2023 · strength 0.18
- Paper NCAPG2 could be an immunological and prognostic biomarker: From pan-cancer analysis to pancreatic cancer validation. DOI 10.3389/fimmu.2023.1097403 ↗
Yuqi Su · 1 shared paper, 2023 · strength 0.16
- Paper A real-world study of anlotinib combined with GS regimen as first-line treatment for advanced pancreatic cancer. DOI 10.3389/fendo.2023.1110624 ↗
Gouling Zhan · 1 shared paper, 2023 · strength 0.16
- Paper A real-world study of anlotinib combined with GS regimen as first-line treatment for advanced pancreatic cancer. DOI 10.3389/fendo.2023.1110624 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.